Real-world data could speed up vaccine approvals, study suggests

Regulators and vaccine makers are exploring whether evidence gathered outside traditional clinical trials can help license new vaccines faster. The shift could reshape how drug companies design studies and when shots reach patients, potentially cutting years from development timelines.

Originaltitel: Alternative approaches to phase III clinical trials for vaccine efficacy and licensure: the role of real-world evidence – a meeting report